NRXPW
NRx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.01
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.3M | 1.2M | — | — | — |
| Cost of Revenue | 1.4M | 505.0K | 5.0K | 5.0K | 4.0K |
| Gross Profit | 851.0K | 720.0K | (5.0K) | (5.0K) | (4.0K) |
| Operating Expenses | |||||
| R&D Expense | 4.3M | 3.8M | 6.2M | 13.4M | 17.0M |
| SG&A Expense | 13.8M | 13.1M | 13.5M | 14.2M | 27.3M |
| General & Admin Expense | 2.7M | 13.1M | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | 106.0K | — | — | — |
| Total Operating Expenses | 18.0M | 16.9M | 19.7M | 27.6M | 44.3M |
| Cost and Expenses | 19.5M | 17.4M | 19.7M | 27.6M | 44.3M |
| Operating Income (EBIT) | (17.2M) | (16.2M) | (19.7M) | (27.6M) | (44.3M) |
| Non-Operating | |||||
| Interest Income | 13.0K | 12.0K | 44.0K | 494.0K | 249.0K |
| Interest Expense | 904.0K | 671.0K | 1.1M | 120.0K | — |
| Net Interest Income | (891.0K) | (659.0K) | (1.0M) | 374.0K | 249.0K |
| Other Non-Op Income/Expense | (7.4M) | (12.4M) | (5.4M) | (2.6M) | 4.6M |
| Non-Operating Income (excl Interest) | 6.4M | 11.7M | 4.3M | 2.4M | (4.6M) |
| EBT (Pre-Tax Income) | (24.5M) | (28.6M) | (25.1M) | (30.1M) | (39.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (24.5M) | (28.6M) | (25.1M) | (30.1M) | (39.8M) |
| Earnings from Cont. Ops | (24.5M) | (28.6M) | (25.1M) | (30.1M) | (39.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (24.5M) | (28.6M) | (25.1M) | (30.2M) | (39.8M) |
| Per Share | |||||
| Basic EPS | ($1.28) | ($1.34) | ($2.39) | ($3.98) | ($0.60) |
| Diluted EPS | ($1.28) | ($1.34) | ($2.39) | ($3.98) | ($0.60) |
| Revenue Per Share | $0.07 | $0.06 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 32.3M | 21.4M | 10.5M | 7.6M | 65.8M |
| Diluted Shares Outstanding | 32.3M | 21.4M | 10.5M | 7.6M | 65.8M |
| Profitability Metrics | |||||
| EBITDA | (23.3M) | (27.8M) | (24.0M) | (30.0M) | (39.8M) |
| D&A | 306.0K | 143.0K | 5.0K | 5.0K | 4.0K |
| EBIT | (23.6M) | (28.0M) | (24.0M) | (30.0M) | (39.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026